Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 13, 2021 - Issue
Submit an article Journal homepage
212
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients

Leorah Freeman1 Dell Medical School, The University of Texas at Austin, TX, USACorrespondence[email protected]
View further author information
,
Arianna Kee2 Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Marc Tian2 Bristol Myers Squibb, Princeton, NJ, USAView further author information
&
Rina Mehta2 Bristol Myers Squibb, Princeton, NJ, USAView further author information
Pages 65-75 | Published online: 22 Jan 2021

References

  • Hunter SF. Overview and diagnosis of multiple sclerosis. Am J Manag Care. 2016;22(Suppl 6):S141–150.
  • Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–e1040. doi:10.1212/WNL.0000000000007035
  • Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008;255(2):280–287. doi:10.1007/s00415-008-0743-8
  • Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol. 2014;122:269–290.
  • Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2
  • O’Connell K, Kelly SB, Fogarty E, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord. 2014;3(6):678–683. doi:10.1016/j.msard.2014.09.002
  • Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–1929. doi:10.1093/brain/awq118
  • Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95(5):986–995.e981. doi:10.1016/j.apmr.2013.10.032
  • Owens GM. Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am J Manag Care. 2016;22(6 Suppl):s151–158.
  • Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med. 2014;275(4):350–363. doi:10.1111/joim.12203
  • Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEconomics Outcomes Res. 2017;9:251–260. doi:10.2147/CEOR.S130334
  • Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788. doi:10.1212/WNL.0000000000005347
  • Anderson SS, Philbrick AM. Improving multiple sclerosis care: an analysis of the necessity for medication therapy management services among the patient population. J Manag Care Specialty Pharmacy. 2014;20(3):254–261.
  • Sánchez Martínez I, Cerdán Sánchez M, López Román J, et al. Possible influence of the route of treatment administration on treatment adherence in patients with multiple sclerosis. Clin Ther. 2020;42(5):e87–e99. doi:10.1016/j.clinthera.2020.03.005
  • Thach AV, Brown CM, Herrera V, et al. Associations between treatment satisfaction, medication beliefs, and adherence to disease-modifying therapies in patients with multiple sclerosis. Int J MS Care. 2018;20(6):251–259. doi:10.7224/1537-2073.2017-031
  • Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):789–800. doi:10.1212/WNL.0000000000005345
  • Parise H, Laliberte F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci. 2013;330(1–2):71–77. doi:10.1016/j.jns.2013.04.007
  • Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol. 2011;11:122. doi:10.1186/1471-2377-11-122
  • Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469–476. doi:10.18553/jmcp.2002.8.6.469
  • Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625. doi:10.3111/13696998.2010.523670
  • Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9. doi:10.2147/PPA.S8230

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.